{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T09:19:50Z","timestamp":1789463990873,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2014,4,27]],"date-time":"2014-04-27T00:00:00Z","timestamp":1398556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1007\/s13277-014-1945-6","type":"journal-article","created":{"date-parts":[[2014,4,28]],"date-time":"2014-04-28T15:12:43Z","timestamp":1398697963000},"page":"7249-7258","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer"],"prefix":"10.1007","volume":"35","author":[{"given":"Blanca","family":"Ortiz-Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Aznar-Oroval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Garc\u00eda","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo Covisa","family":"Peris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar Perez","family":"Ballestero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Sanchez","family":"Yepes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s Garcia","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Illueca","family":"Ballester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique Garc\u00eda","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,27]]},"reference":[{"issue":"5","key":"1945_CR1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel RXJ, Sala E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277\u2013300.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"1945_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1525-1438.2006.00319.x","volume":"16","author":"T Paulsen","year":"2006","unstructured":"Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16 Suppl 1:11\u20137.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"1945_CR3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.21616","volume":"106","author":"MJ Engelen","year":"2006","unstructured":"Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynaecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106(3):589\u201398.","journal-title":"Cancer"},{"issue":"12","key":"1945_CR4","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","volume":"54","author":"CM Sturgeon","year":"2008","unstructured":"Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11\u201379.","journal-title":"Clin Chem"},{"issue":"1","key":"1945_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.humrep.a136832","volume":"4","author":"I Jacobs","year":"1989","unstructured":"Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1\u201312.","journal-title":"Hum Reprod"},{"key":"1945_CR6","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000217776","volume":"13","author":"R Molina","year":"1992","unstructured":"Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, et al. A prospective study of tumour markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumour Biol. 1992;13:278\u201386.","journal-title":"Tumour Biol"},{"key":"1945_CR7","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000181180","volume":"29","author":"R Molina","year":"2008","unstructured":"Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG 72.3 as tumour markers in patients with lung cancer: comparison with CYFRA 21\u20131, CEA, SCC and NSE. Tumour Biol. 2008;29:371\u201380.","journal-title":"Tumour Biol"},{"key":"1945_CR8","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000224628","volume":"30","author":"R Molina","year":"2009","unstructured":"Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumour markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol. 2009;30:121\u20139.","journal-title":"Tumour Biol"},{"key":"1945_CR9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1634\/theoncologist.2-1-6","volume":"2","author":"M Markman","year":"1997","unstructured":"Markman M. The role of CA-125 in the management of ovarian cancer. Oncologist. 1997;2:6\u20139.","journal-title":"Oncologist"},{"key":"1945_CR10","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/37.8.1379","volume":"37","author":"R Molina","year":"1991","unstructured":"Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991;37:1379\u201383.","journal-title":"Clin Chem"},{"key":"1945_CR11","doi-asserted-by":"crossref","unstructured":"Menon U, Gentry-Maharaj A, Hallet R, Ryan A, Burnell M, Sharma A et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer , and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10 (4):327-340. available http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21642681","DOI":"10.1016\/S1470-2045(09)70026-9"},{"key":"1945_CR12","doi-asserted-by":"crossref","unstructured":"Patridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113 (4):775-782. available http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19305319","DOI":"10.1097\/AOG.0b013e31819cda77"},{"key":"1945_CR13","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0002-9378(84)90035-8","volume":"149","author":"RC Bast Jr","year":"1984","unstructured":"Bast Jr RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19\u20139, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984;149:553\u20139.","journal-title":"Am J Obstet Gynecol"},{"issue":"Suppl 3","key":"1945_CR14","first-page":"274","volume":"15","author":"RC Bast Jr","year":"2005","unstructured":"Bast Jr RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumour markers: CA 125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl 3:274\u201381.","journal-title":"Int J Gynecol Cancer"},{"key":"1945_CR15","first-page":"609","volume":"30","author":"A Dalen van","year":"2009","unstructured":"van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, et al. Significance of serum CA 125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaecol Oncol. 2009;30:609\u201315.","journal-title":"Eur J Gynaecol Oncol"},{"issue":"13","key":"1945_CR16","first-page":"3695","volume":"63","author":"I Hellstrom","year":"2003","unstructured":"Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695\u2013700.","journal-title":"Cancer Res"},{"key":"1945_CR17","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162\u20139.","journal-title":"Cancer Res"},{"key":"1945_CR18","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumour biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402\u20138.","journal-title":"Gynecol Oncol"},{"key":"1945_CR19","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2008.04.041","volume":"110","author":"L Havrilesky","year":"2008","unstructured":"Havrilesky L, Whitehead C, Rubatt J, Cheek R, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374\u201382.","journal-title":"Gynecol Oncol"},{"key":"1945_CR20","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","volume":"117","author":"B Nolen","year":"2010","unstructured":"Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast Jr RC, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117:440\u20135.","journal-title":"Gynecol Oncol"},{"issue":"11","key":"1945_CR21","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1373\/clinchem.2010.157073","volume":"57","author":"JM Escudero","year":"2011","unstructured":"Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. The utility of serum human epididymis protein 4 (HE4) in patients with malignant and non malignant diseases: comparison with CA 125. Clin Chem. 2011;57(11):1534\u201344.","journal-title":"Clin Chem"},{"key":"1945_CR22","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","volume":"19","author":"M Galgano","year":"2006","unstructured":"Galgano M, Hampton G, Frierson HJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847\u201353.","journal-title":"Mod Pathol"},{"key":"1945_CR23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","volume":"110","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Craig Miller M, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110:196\u2013201.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"1945_CR24","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1515\/cclm-2012-0097","volume":"50","author":"L Hertlein","year":"2012","unstructured":"Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012;50(12):2181\u20138.","journal-title":"Clin Chem Lab Med"},{"key":"1945_CR25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","volume":"112","author":"RG Moore","year":"2009","unstructured":"Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Craig Miller M, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and Ca125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40\u20136.","journal-title":"Gynecol Oncol"},{"issue":"10\u201311","key":"1945_CR26","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.clinbiochem.2011.04.011","volume":"44","author":"Y Park","year":"2011","unstructured":"Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44(10\u201311):884\u20138. doi: 10.1016\/j.clinbiochem.2011.04.011 .","journal-title":"Clin Biochem"},{"key":"1945_CR27","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","volume":"100","author":"K Huhtinen","year":"2009","unstructured":"Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315\u20139.","journal-title":"Br J Cancer"},{"key":"1945_CR28","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ajog.2010.03.043","volume":"203","author":"RG Moore","year":"2010","unstructured":"Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:228\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"1945_CR29","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","volume":"99","author":"DG Rosen","year":"2005","unstructured":"Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267\u201377.","journal-title":"Gynecol Oncol"},{"key":"1945_CR30","unstructured":"National Institute for Health and Clinical Excellence (NICE): Guidance. Ovarian cancer: the recognition and initial management of ovarian cancer. National Collaborative Centre for Cancer (UK). Cardiff, UK: National Collaborative Centre for Cancer, 2011."},{"key":"1945_CR31","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.ygyno.2009.10.087","volume":"116","author":"MR Andersen","year":"2010","unstructured":"Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, et al. Use of Symptom Idex, Ca125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378\u201383.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"1945_CR32","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1515\/CCLM.2011.709","volume":"49","author":"M Lenhard","year":"2011","unstructured":"Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, F\u00fcrst S, Mayr D, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA 125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011;49(12):2081\u20138.","journal-title":"Clin Chem Lab Med"},{"issue":"7458","key":"1945_CR33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/bmj.329.7458.168","volume":"329","author":"JJ Deeks","year":"2004","unstructured":"Deeks JJ, Almant DG. Diagnostics test 4: likelihood ratios. BMJ. 2004;329(7458):168\u20139.","journal-title":"BMJ"},{"key":"1945_CR34","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1007\/s13277-011-0204-3","volume":"32","author":"R Molina","year":"2011","unstructured":"Molina R, Escudero JM, Aug\u00e9 JM, Filella X, Foj L, Torne A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with Ca125 and ROMA algoritm in patients with gynaecological diseases. Tumor Biol. 2011;32:1087\u201395.","journal-title":"Tumor Biol"},{"key":"1945_CR35","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/ijc.26129","volume":"130","author":"Y Park","year":"2012","unstructured":"Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012;130:1136\u201344.","journal-title":"Int J Cancer"},{"key":"1945_CR36","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","volume":"104","author":"T Gorp Van","year":"2011","unstructured":"Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and Ca125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104:863\u201370.","journal-title":"Br J Cancer"},{"key":"1945_CR37","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1158\/1055-9965.EPI-11-0635","volume":"20","author":"E Bandiera","year":"2011","unstructured":"Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnositic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496\u2013506.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"8","key":"1945_CR38","first-page":"1439","volume":"50","author":"S Yu","year":"2012","unstructured":"Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med. 2012;50(8):1439\u201346.","journal-title":"Clin Chem Lab Med"},{"key":"1945_CR39","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1136\/jclinpath-2012-201031","volume":"66","author":"S Ferraro","year":"2013","unstructured":"Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzolli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273\u201381.","journal-title":"J Clin Pathol"},{"issue":"1","key":"1945_CR40","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ejogrb.2012.10.036","volume":"167","author":"J Lin","year":"2013","unstructured":"Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynaecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):81\u20135.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"1945_CR41","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/1471-2407-12-258","volume":"12","author":"F Li","year":"2012","unstructured":"Li F, Ruxiu T, Chang K, Wang F, Deng S, Lu W, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and Ca125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer. 2012;12:258\u201376.","journal-title":"BMC Cancer"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1945-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-014-1945-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-014-1945-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T13:09:43Z","timestamp":1597756183000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-014-1945-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,27]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["1945"],"URL":"https:\/\/doi.org\/10.1007\/s13277-014-1945-6","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,27]]}}}